cct301
Cell therapyexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 26, 2018 (NCT03393936)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tyrosine-protein kinase transmembrane receptor ROR2Immunity, passive
ROR2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05128786 | Phase 1 | Nov 20, 2021 | Fudan University, Shanghai PerHum Therapeutics Co., Ltd. |
| NCT03960060 | Phase 1 | May 16, 2019 | Fudan University, Sinobioway Cell Therapy Co., Ltd. |
| NCT03393936 | Phase 1/Phase 2 (Phase 2) | Mar 26, 2018 | Sinobioway Cell Therapy Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fudan University | Academic/Hospital | 2 | 0 | 1 | 2019 |
| Sinobioway Cell Therapy Co., Ltd. | For profit | 2 | 2 | 2 | 2018 |
| Shanghai PerHum Therapeutics Co., Ltd. | For profit | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1